Company Overview and News
Chicago, IL – May 10, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include L3 Technologies, Inc. (LLL - Free Report) , Spirit AeroSystems, Inc. (SPR - Free Report) , Leidos Holdings, Inc. (LDOS - Free Report) , Huntington Ingalls Industries, Inc.
Leidos (NYSE: LDOS), a FORTUNE 500® science, information technology, and engineering leader, was awarded 7 task orders by the National Geospatial-Intelligence Agency (NGA) under the Multi-Intelligence Analytical & Collection Support Services (MACSS) program. The task orders will be executed over the next five and a half years at a total contract value of approximately $250 million. Work will be primarily performed in Springfield, Va.
With more than 409 S&P 500 companies having released their quarterly results, the Q1 earnings season is set to enter its last leg. As of May 4, of these 409 index members which revealed their earnings numbers, 78% delivered an earnings beat, while 75.6% surpassed revenue estimates.
Stocks were up on Monday but in Tuesday’s premarket were soft and looking for direction ahead of the president’s decision on the Iran nuke deal. The trend of endless buying the dips has not worked well lately, and many investors are wondering whether the best has been seen for 2018. Now investors have to consider how they want their investments positioned for the longer term.
Leidos Holdings, Inc. (LDOS - Free Report) reported first-quarter 2018 adjusted earnings of $1.03 per share, which came in line with the Zacks Consensus Estimate. Earnings improved 17% from the year-ago quarter's figure of 88 cents.
Document Table of Contents
The following slide deck was published by Leidos Holdings, Inc. in conjunction with their 2018 Q1 earnings call.
Over the last week, Wall Street saw first-quarter 2018 earnings releases from several defense biggies like Lockheed Martin, Boeing, Northrop Grumman and General Dynamics. L-3 Technologies (LLL - Free Report) kick-started this week by reporting better-than-expected result for the first quarter. Today, Spirit AeroSystems (SPR - Free Report) is set to release Q1 numbers.
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Purs
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A <
Leidos (NYSE: LDOS), a global science and technology leader, was awarded a prime contract by the U.S. Army to continue to provide logistics services to the 1 st Theater Sustainment Command (TSC) in support of U.S. Army Central (ARCENT), the Army component of U.S. Central Command (CENTCOM). The single-award cost-plus fixed-fee/cost-plus incentive-fee contract has a one-year base period of performance, five one-year options, and a total contract value of approximately $112 million .
Document UNITED STATES
* LEIDOS HOLDINGS - AWARDED A FOLLOW-ON TASK ORDER BY GENERAL SERVICES ADMINISTRATION TO SUPPORT U.S. ARMY’S C4ISR PROTOTYPING OPERATIONS
15m - Asif
BUSINESS TrovaGene is a clinical-stage, precision medicine oncology therapeutics company. The company's primary focus is to develop oncology therapeutics for improved cancer care and to optimize drug development by leveraging its proprietary Precision Cancer Monitoring® (“PCM”) technology in tumor genomics. The company's lead drug candidate, PCM-075, is a Polo-like Kinase 1 (“PLK1”) selective adenosine triphosphate (“ATP”) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and synergy in combination with more than ten different chemotherapeutics and targeted therapies, such as Zytiga® (abiraterone acetate), Beleodaq® (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade® (bortezomib) in Acute Myeloid Leukemia (“AML”), metastatic Castration-Resistant Prostate Cancer (“mCRPC”) and other hematologic and solid tumor cancers. On March 15, 2017, the company announced the licensing of PCM-075, a PLK1 inhibitor...
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
as of ET